On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies
September 12th 2012A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.
Read More